Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Junpei Kawauchi is active.

Publication


Featured researches published by Junpei Kawauchi.


PLOS ONE | 2015

MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers

Motohiro Kojima; Hiroko Sudo; Junpei Kawauchi; Satoko Takizawa; Satoshi Kondou; Hitoshi Nobumasa; Atsushi Ochiai

It is difficult to detect pancreatic cancer or biliary-tract cancer at an early stage using current diagnostic technology. Utilizing microRNA (miRNA) markers that are stably present in peripheral blood, we aimed to identify pancreatic and biliary-tract cancers in patients. With “3D-Gene”, a highly sensitive microarray, we examined comprehensive miRNA expression profiles in 571 serum samples obtained from healthy patients, patients with pancreatic, biliary-tract, or other digestive cancers, and patients with non-malignant abnormalities in the pancreas or biliary tract. The samples were randomly divided into training and test cohorts, and candidate miRNA markers were independently evaluated. We found 81 miRNAs for pancreatic cancer and 66 miRNAs for biliary-tract cancer that showed statistically different expression compared with healthy controls. Among those markers, 55 miRNAs were common in both the pancreatic and biliary-tract cancer samples. The previously reported miR-125a-3p was one of the common markers; however, it was also expressed in other types of digestive-tract cancers, suggesting that it is not specific to cancer types. In order to discriminate the pancreato-biliary cancers from all other clinical conditions including the healthy controls, non-malignant abnormalities, and other types of cancers, we developed a diagnostic index using expression profiles of the 10 most significant miRNAs. A combination of eight miRNAs (miR-6075, miR-4294, miR-6880-5p, miR-6799-5p, miR-125a-3p, miR-4530, miR-6836-3p, and miR-4476) achieved a sensitivity, specificity, accuracy and AUC of 80.3%, 97.6%, 91.6% and 0.953, respectively. In contrast, CA19-9 and CEA gave sensitivities of 65.6% and 40.0%, specificities of 92.9% and 88.6%, and accuracies of 82.1% and 71.8%, respectively, in the same test cohort. This diagnostic index identified 18/21 operable pancreatic cancers and 38/48 operable biliary-tract cancers in the entire cohort. Our results suggest that the assessment of these miRNA markers is clinically valuable to identify patients with pancreato-biliary cancers who could benefit from surgical intervention.


Cancer Science | 2016

Novel combination of serum microRNA for detecting breast cancer in the early stage.

Akihiko Shimomura; Sho Shiino; Junpei Kawauchi; Satoko Takizawa; Hiromi Sakamoto; Juntaro Matsuzaki; Makiko Ono; Fumitaka Takeshita; Shumpei Niida; Chikako Shimizu; Yasuhiro Fujiwara; Takayuki Kinoshita; Kenji Tamura; Takahiro Ochiya

MicroRNA (miRNA), which are stably present in serum, have been reported to be potentially useful for detecting cancer. In the present study, we examined the expression profiles of serum miRNA in several large cohorts to identify novel miRNA that can be used to detect early stage breast cancer. We comprehensively evaluated the serum miRNA expression profiles using highly sensitive microarray analysis. A total of 1280 serum samples of breast cancer patients stored in the National Cancer Center Biobank were used. In addition, 2836 serum samples were obtained from non‐cancer controls, 451 from patients with other types of cancers, and 63 from patients with non‐breast benign diseases. The samples were divided into a training cohort including non‐cancer controls, other cancers and breast cancer, and a test cohort including non‐cancer controls and breast cancer. The training cohort was used to identify a combination of miRNA that could detect breast cancer, and the test cohort was used to validate that combination. miRNA expressions were compared between patients with breast cancer and non‐breast cancer, and a combination of five miRNA (miR‐1246, miR‐1307‐3p, miR‐4634, miR‐6861‐5p and miR‐6875‐5p) was found to be able to detect breast cancer. This combination had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% for breast cancer in the test cohort. In addition, this combination could detect early stage breast cancer (sensitivity of 98.0% for Tis).


PLOS ONE | 2012

Use of Non-Amplified RNA Samples for Microarray Analysis of Gene Expression

Hiroko Sudo; Atsuko Mizoguchi; Junpei Kawauchi; Hideo Akiyama; Satoko Takizawa

Demand for high quality gene expression data has driven the development of revolutionary microarray technologies. The quality of the data is affected by the performance of the microarray platform as well as how the nucleic acid targets are prepared. The most common method for target nucleic acid preparation includes in vitro transcription amplification of the sample RNA. Although this method requires a small amount of starting material and is reported to have high reproducibility, there are also technical disadvantages such as amplification bias and the long, laborious protocol. Using RNA derived from human brain, breast and colon, we demonstrate that a non-amplification method, which was previously shown to be inferior, could be transformed to a highly quantitative method with a dynamic range of five orders of magnitude. Furthermore, the correlation coefficient calculated by comparing microarray assays using non-amplified samples with qRT-PCR assays was approximately 0.9, a value much higher than when samples were prepared using amplification methods. Our results were also compared with data from various microarray platforms studied in the MicroArray Quality Control (MAQC) project. In combination with micro-columnar 3D-Gene™ microarray, this non-amplification method is applicable to a variety of genetic analyses, including biomarker screening and diagnostic tests for cancer.


Nature Communications | 2018

Integrated extracellular microRNA profiling for ovarian cancer screening

Akira Yokoi; Juntaro Matsuzaki; Yusuke Yamamoto; Yutaka Yoneoka; Kenta Takahashi; Hanako Shimizu; Takashi Uehara; Mitsuya Ishikawa; Shun-ichi Ikeda; Takumi Sonoda; Junpei Kawauchi; Satoko Takizawa; Yoshiaki Aoki; Shumpei Niida; Hiromi Sakamoto; Ken Kato; Tomoyasu Kato; Takahiro Ochiya

A major obstacle to improving prognoses in ovarian cancer is the lack of effective screening methods for early detection. Circulating microRNAs (miRNAs) have been recognized as promising biomarkers that could lead to clinical applications. Here, to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors. A diagnostic model based on expression levels of ten miRNAs is constructed in the discovery set. Validation in an independent cohort reveals that the model is very accurate (sensitivity, 0.99; specificity, 1.00), and the diagnostic accuracy is maintained even in early-stage ovarian cancers. Furthermore, we construct two additional models, each using 9–10 serum miRNAs, aimed at discriminating ovarian cancers from the other types of solid tumors or benign ovarian tumors. Our findings provide robust evidence that the serum miRNA profile represents a promising diagnostic biomarker for ovarian cancer.Screening methods for early detection of ovarian cancer is technically difficult. Here, the authors investigated circulating microRNA in human blood serum and developed a model using 10 microRNAs to discern between ovarian cancer and being ovarian tumors, solid tumors, and non-cancer patients.


Cancer Research | 2017

Abstract P4-07-04: Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

A Shimomura; S Shiino; Junpei Kawauchi; Satoko Takizawa; Hiromi Sakamoto; Chikako Shimizu; Fumitaka Takeshita; S Niida; Takayuki Kinoshita; Kenji Tamura; Takahiro Ochiya

[Background] It is recently reported that microRNAs (miRNAs) are stably present in serum and potentially useful in the diagnosis and evaluation of treatment of cancer. [Materials and Methods] Serum samples of breast cancer before treatment (n=1280) between 2008 and 2014 were obtained from National Cancer Center Hospital and controls (n=3348) were obtained from collaborative institutes. Additionally, the serum sample of patients who received neoadjuvant chemotherapy (NAC) and surgery between last chemotherapy administration and surgery were collected. A comprehensive quantitative expression analysis of miRNA was performed using the by DNA chip “3D-Gene® (Toray Industries Inc.)” Clinicopathological data was retrieved from medical records. Pathological complete response (pCR) was defined as the absence of residual invasive and in situ cancer of the resected breast specimen and all sampled regional lymph nodes. [Results] Serum samples before treatment of breast cancer patients (n=74), non-cancer controls and patients with other cancers were used (n=2007) in a training set. The rest except for samples after NAC were used in a test set. The formula with the combination of five miRNAs (miR-1246, miR-1307-3p, miR-4634, miR-6861-5p, and miR-6875-5p) was found to be able to detect breast cancer (BCmiR set). BCmiR set had a sensitivity of 97.3%, specificity of 82.9% and accuracy of 89.7% in the test cohort. BCmiR set could detect breast cancer in the non-invasive stage (sensitivity of 98.0% for Tis). In the breast cancer patients, 91 patients received NAC and surgery. Median age of NAC patients was 49 years (range 28-77). Forty-two patients were hormone receptor-positive (HR+) and HER2-negative (HER2-), 24 were HR+ and HER2-positive (HER2+), 11 were hormone receptor-negative (HR-) and HER2+ and 14 were HR- and HER2-. pCR was observed in 19 (20.9%) of NAC patients. pCR in each subtypes were 3 (7.7%) in HR+ and HER2-, 6 (33.3%) in HR+ and HER2+, 4 (57.1%) in HR- and HER2+ and 3 (27.3%) in HR- and HER2-. Serum after NAC were obtained from 19 pCR patients and 71 non-pCR patients. When we applied BCmiR set to the serum samples after NAC, the average diagnostic index (cut-off value=0) in pCR patients was significantly lower than that in non-pCR patients (pCR, -0.30±0.84; non-pCR, 0.31±1.15; p=0.03). In fact, 57.9% of pCR patients were classified into non-breast cancer. However, 40.8% of non-pCR patients were misclassified into non-breast cancer. [Conclusion] The combination of five miRNAs (BCmiR set) measured from serum can be used to detect breast cancer. BCmiR set has potential to predict pCR in patients who received NAC. The further analysis to predict pCR is underway and further results will be presented in the symposium. Citation Format: Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Shimizu C, Takeshita F, Niida S, Kinoshita T, Tamura K, Ochiya T. Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-07-04.


Cancer Research | 2017

Abstract 5678: Novel serum microRNAs that enable liquid biopsy for colorectal cancer: validation study of large cohort

Hiroyuki Takamaru; Yutaka Saito; Taku Sakamoto; Seiichiro Abe; Masayoshi Yamada; Takeshi Nakajima; Kazuki Sudo; Ken Kato; Junpei Kawauchi; Satoko Takizawa; Hiromi Sakamoto; Motohiro Kojima; Atsushi Ochiai; Shumpei Niida; Hideshi Ishii; Tomoko Takamaru; Juntaro Matsuzaki; Takahisa Matsuda; Takahiro Ochiya

Introduction: Recent studies have reported that serum microRNAs (miRNAs) are potentially useful biomarkers for cancer. However, the detection system using serum miRNAs is not established in colorectal cancer (CRC). The aims of this study are 1) to identify specific serum miRNAs and establish the discriminant model for CRC detection and 2) to validate the miRNAs and the discriminant model using a large cohort. Methods: First, we identified serum miRNAs related with the presence of CRC and constructed the discriminant model for CRC detection using the publicly-released serum miRNA database including 50 patients with CRC and 90 healthy individuals (GSE59856 and GSE73002). Comparing serum miRNA levels between patients with CRC and healthy individuals, we picked up miRNAs (p 2). Using these miRNAs, Fisher’s linear discriminant analysis was performed and the diagnostic models were constructed using less than 7 miRNAs. Subsequently, 1117 patients of National Cancer Center Hospital with CRC were enrolled as a validation cohort. Patients with the following criteria were excluded; (i) patients simultaneously or previously diagnosed as the other cancers, (ii) patients who were treated for CRC previously and (iii) patients with familial adenomatous polyposis or Lynch syndrome. Control blood samples were obtained from patients without any history of cancer who were admitted or referred to National Center for Geriatrics and Gerontology or Yokohama Minoru Clinic between 2010 and 2015. A total of 1013 CRC patients and 4384 non-cancerous patients were analyzed. Total RNA was extracted from 300 micro L of serum and comprehensive miRNA expression analysis was performed using a 3D-Gene microarray. ROC analysis was performed to evaluate the previous discriminant models. The sensitivity in each pathological stage and location of CRC was also investigated.This research is partially supported by the “Development of Diagnostic Technology for Detection of miRNA in Body Fluids” grant from the Japan Agency for Medical Research and Development (AMED). Results:First we picked up 30 miRNAs for CRC diagnosis. Fisher’s analysis revealed 107611 candidates of numerical formulas, that showed > 80% of sensitivity and specificity. We could narrow these candidates to 43 formulas with validation analysis. By ROC analysis, the AUC, sensitivity and specificity of the discriminant formula with best performance was 0.904, 79.6% and 86.5%, respectively. The sensitivities of each pathological stage were as follows; pStage 0: 79.0%, pStage I: 90.7%, pStage II: 85.1%, pStage III: 73.7%, pStage IV: 62.2%. The sensitivity of CRC in the right side of the colon was 79.4%, whereas that in the left side was 79.7%. Conclusions:We identified novel serum miRNAs for CRC detection. Our discriminant using these miRNAs can diagnose CRC including early stage. Furthermore, the sensitivity was high irrespective of the tumor location. Citation Format: Hiroyuki Takamaru, Yutaka Saito, Taku Sakamoto, Seiichiro Abe, Masayoshi Yamada, Takeshi Nakajima, Kazuki Sudo, Ken Kato, Junpei Kawauchi, Satoko Takizawa, Hiromi Sakamoto, Motohiro Kojima, Atsushi Ochiai, Shumpei Niida, Hideshi Ishii, Tomoko Takamaru, Juntaro Matsuzaki, Takahisa Matsuda, Takahiro Ochiya. Novel serum microRNAs that enable liquid biopsy for colorectal cancer: validation study of large cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5678. doi:10.1158/1538-7445.AM2017-5678


Gastroenterology | 2015

Sa1940 microRNA Markers for the Diagnosis of Pancreatic and Bile Duct Cancers

Motohiro Kojima; Hiroko Sudo; Junpei Kawauchi; Satoko Takizawa; Satoshi Kondou; Hitoshi Nobumasa; Atsushi Ochiai

It is recently reported that microRNAs (miRNAs) are stably present in serum and potentially useful in the diagnosis of cancer. Using highly sensitive microarray, 3D-Gene®, we examined comprehensive miRNA expression profiles in serum obtained from 66 pancreatic cancer patients, 66 bile duct cancer patients and 100 matched healthy volunteer as the study set, and found that 122 miRNA markers for pancreatic cancer and 125 miRNA markers for bile duct cancer differentiated pancreatic / bile duct cancer patients from healthy control with a statistical significance. We then validated the diagnostic performance of these markers using serum obtained from 33 pancreatic cancer patients, 33 bile duct cancer patients and 50 healthy controls. One of the single miRNA markers for pancreatic cancer yielded more than 90% diagnostic sensitivity and specificity, and combined use of two markers perfectly differentiated cancer and healthy samples. We also found that over 100 miRNA markers of pancreatic cancer overlapped with miRNA markers of bile duct cancer. Our results suggest that these miRNA markers have clinical values to screen out pancreatic and bile duct cancer patients.


Anticancer Research | 2014

Gene Expression Analysis Using a Highly Sensitive DNA Microarray for Colorectal Cancer Screening

Yoshikatsu Koga; Nobuyoshi Yamazaki; Satoko Takizawa; Junpei Kawauchi; Osamu Nomura; Seiichiro Yamamoto; Norio Saito; Yasuo Kakugawa; Yosuke Otake; Minori Matsumoto; Yasuhiro Matsumura


Archive | 2017

STOMACH CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD

Satoko Kozono; Hitoshi Nobumasa; Satoshi Kondou; Hiroko Sudo; Junpei Kawauchi; Atsushi Ochiai; Motohiro Kojima


Archive | 2017

Breast cancer detection kit or device, and method for detecting breast cancer

Satoshi Kondou; Hitoshi Nobumasa; Satoko Kozono; Hiroko Sudo; Junpei Kawauchi; Takahiro Ochiya; Nobuyoshi Kosaka; Makiko Ono; Kenji Tamura

Collaboration


Dive into the Junpei Kawauchi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge